Loading
CARGO developed a CAR T-cell therapy aimed at a protein called CD22 for patients with large B-cell lymphoma whose cancer had come back after CD19 CAR T treatment. It went public in 2023 and was bought by Concentra Biosciences in 2025 after winding down development.
CARGO Therapeutics was a clinical-stage cell therapy company whose lead candidate, CRG-022, was an autologous CD22-directed chimeric antigen receptor (CAR) T-cell product for relapsed or refractory large B-cell lymphoma, including patients who had progressed after CD19 CAR T-cell therapy. The company began a potentially pivotal phase 2 trial (NCT05972720) in 2023 and completed a Nasdaq IPO raising about $281 million in November 2023. In July 2025 CARGO, by then describing itself as a company that had focused on CAR T-cell development, agreed to be acquired by Concentra Biosciences for $4.379 per share in cash plus a contingent value right tied to closing net cash above $217.5 million and to any disposition of remaining product candidates. The tender offer closed on 18 August 2025 and the merger completed the next day.
Investors not recorded; see the round sources.
Amounts only where the cited source states them. Rounds without a public source are not listed.